帕克替尼与安慰剂治疗重症COVID-19的疗效与安全性:2期随机临床试验
这项2期、双盲、安慰剂对照随机临床试验在美国21个中心纳入200例住院重症COVID-19成人患者,按1:1随机接受标准治疗加帕克替尼(第1天400 mg口服,第2-14天200 mg每日两次)或安慰剂,疗程14天。主要终点为第28天死亡或需要有创机械通气(IMV)或体外膜肺氧合(ECMO)。帕克替尼组主要终点发生率为17.2%(17例),安慰剂组为22.8%(23例)(OR 0.62,95%CI 0.28-1.35,P=0.23),未达统计学显著。在白细胞介素6升高患者中,帕克替尼组发生率为17.5%(11/63),安慰剂组为30.4%(21/96)。不良事件发生率两组相似,帕克替尼组3级及以上不良事件发生率低于安慰剂组(29.2% vs 40.6%)。作者认为亚组分析可能提示存在可从帕克替尼获益的高炎症特定人群,但需进一步临床试验确认。
要点
- 主要终点(第28天死亡或需IMV/ECMO)帕克替尼组17.2%(17例)vs 安慰剂组22.8%(23例),OR 0.62(95%CI 0.28-1.35),P=0.23,未达统计学显著。
- 在白细胞介素6升高患者中,帕克替尼组主要终点发生率17.5%(11/63)vs 安慰剂组30.4%(21/96)。
- 帕克替尼组不良事件发生率78.1%(75例)vs 安慰剂组80.2%(81例);感染14.6%(14例)vs 19.8%(20例),出血8.3%(8例)vs 10.9%(11例),血栓8.3%(8例)vs 7.9%(8例)。
- 帕克替尼组3级及以上不良事件发生率29.2%(28例)低于安慰剂组40.6%(41例)。
- 作者结论:研究未达主要终点;亚组分析可能提示高炎症特定人群可获益,但需进一步临床试验确认。
适用人群与场景
- 美国21个中心住院的成人重症COVID-19患者,2020年6月至2021年2月入组;帕克替尼组99例(男性56例,56.6%;中位年龄60岁,范围19-87岁),安慰剂组101例(男性64例,63.4%;中位年龄59岁,范围28-94岁)。
- 帕克替尼组需补充氧气的比例为99.0%(98例),安慰剂组为98.0%(99例)。
处置流程与药物剂量
- 标准治疗加帕克替尼:第1天400 mg口服,第2-14天200 mg每日两次,疗程14天。
- 对照组为标准治疗加安慰剂,疗程14天。
研究设计与关键结果
- 2期、双盲、安慰剂对照随机临床试验,美国21个中心,200例重症COVID-19住院成人,1:1随机接受标准治疗加帕克替尼(99例)或安慰剂(101例),每例安全性随访约1.5个月。
- 主要终点第28天死亡或需IMV或ECMO:帕克替尼组17.2%(17例)vs 安慰剂组22.8%(23例),OR 0.62(95%CI 0.28-1.35),P=0.23。
- 白细胞介素6升高患者主要终点发生率:帕克替尼组17.5%(11/63)vs 安慰剂组30.4%(21/96)。
- 不良事件发生率:帕克替尼组78.1%(75例)vs 安慰剂组80.2%(81例);感染14.6%(14例)vs 19.8%(20例);出血8.3%(8例)vs 10.9%(11例);血栓8.3%(8例)vs 7.9%(8例)。
- 3级及以上不良事件发生率:帕克替尼组29.2%(28例)低于安慰剂组40.6%(41例)。
证据类型、等级与局限
- 证据类型:2期、双盲、安慰剂对照随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:研究未达主要终点;亚组分析可能提示高炎症特定人群可获益,但需进一步临床试验确认。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The morbidity and mortality associated with COVID-19 remain high despite advances in standard of care therapy, and the role of anti-inflammatory agents that inhibit the interleukin 6/JAK2 pathway is still being elucidated.
OBJECTIVE: To evaluate the efficacy and safety of the oral JAK2/IRAK1 inhibitor pacritinib vs placebo in the treatment of adults with severe COVID-19.
DESIGN, SETTING, AND PARTICIPANTS: This phase 2, double-blind, placebo-controlled, randomized clinical trial enrolled hospitalized adult patients with severe COVID-19 at 21 centers across the US between June 2020 and February 2021, with approximately 1.5 months of safety follow-up per patient. Data analysis was performed from September 2021 to July 2022.
INTERVENTIONS: Patients were randomized 1:1 to standard of care plus pacritinib (400 mg per os on day 1 followed by 200 mg twice daily on days 2-14) vs placebo, for 14 days.
MAIN OUTCOMES AND MEASURES: The primary end point was death or need for invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) by day 28. All-cause mortality and safety were also assessed.
RESULTS: A total of 200 patients were randomized to pacritinib (99 patients; 56 men [56.6%]; median [range] age, 60 [19-87] years) or placebo (101 patients; 64 men [63.4%]; median [range] age 59 [28-94] years). The percentage requiring supplementary oxygen was 99.0% (98 patients) in the pacritinib group vs 98.0% (99 patients) in the placebo group. The percentage who progressed to IMV, ECMO, or death was 17.2% (17 patients) in the pacritinib group vs 22.8% (23 patients) in the placebo group (odds ratio, 0.62; 95% CI, 0.28-1.35; P = .23). Among patients with elevated interleukin 6, the rate was 17.5% (11 of 63 patients) in the pacritinib group vs 30.4% (21 of 96 patients) in the placebo group. The adverse event rate was similar for pacritinib vs placebo (78.1% [75 patients] vs 80.2% [81 patients]), with no excess in infection (14.6% [14 patients] vs 19.8% [20 patients]), bleeding (8.3% [8 patients] vs 10.9% [11 patients]), or thrombosis (8.3% [8 patients] vs 7.9% [8 patients]). Rates of grade 3 or higher adverse events were lower with pacritinib than placebo (29.2% [28 patients] vs 40.6% [41 patients]).
CONCLUSIONS AND RELEVANCE: The study did not meet its primary end point in patients with severe COVID-19. Subgroup analyses may indicate specific populations with hyperinflammation that could benefit from pacritinib, although further clinical trials would be needed to confirm these effects.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04404361.
参考来源
- Cafardi J, Miller C, Terebelo H, et al. Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2022. PMID: 36469321. doi:10.1001/jamanetworkopen.2022.42918
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。